ICU Clinical Pathway for Therapeutic Hypothermia Treatment for Neonates with Hypoxic Ischemic Encephalopathy (HIE)
- Related Pathways
- EEG Monitoring
- Status Epilepticus
Expedite transfer for therapeutic hypothermia as possible
within 6 hours of life OR Begin active/passive cooling
- Review Eligibility Criteria
- Birth History, Physical Examination
- Assess:
- Contact Numbers for CHOP
- Neonatology Consult
- 215-590-3083
- Transport Request
- 215-590-2160
- Other Neuroprotective Therapies
Research trials currently closed to enrollment and in follow-up. - HEAL: High-dose EPO for Asphyxia & Encephalopathy
- Preterm HIE
Patient Transported
- FLOC/RN Team Assessment
- Admission Evaluation, Degree of Encephalopathy
- Laboratory Testing
Neurological Monitoring
Imaging Studies
Imaging Studies
Patient Eligible for Therapeutic Hypothermia
- Initiate Whole Body Therapeutic Hypothermia
- Neurological Monitoring
Posted: December 2018
Revised: April 2021
Authors: Flibotte, J. MD; Dysart, K. MD; Stoller, J. MD; Vossough, A. MD; Billinghurst, L. MD; Abend, N. MD;
Massey, S. MD; Cook, N. MD; Hufnal, C. MD; Heimall, L. MSN; Fung, F. MD; Fitzgerald, M. MD; A. Bustin, PharmD; S. Sadashiv, MD
Revised: April 2021
Authors: Flibotte, J. MD; Dysart, K. MD; Stoller, J. MD; Vossough, A. MD; Billinghurst, L. MD; Abend, N. MD;
Massey, S. MD; Cook, N. MD; Hufnal, C. MD; Heimall, L. MSN; Fung, F. MD; Fitzgerald, M. MD; A. Bustin, PharmD; S. Sadashiv, MD
Evidence
- Hypothermia and Neonatal Encephalopathy
- Cooling for Newborns with Hypoxic Ischaemic Encephalopathy
- Effect of Depth and Duration of Cooling on Deaths in the NICU Among Neonates With Hypoxic Ischemic Encephalopathy
- Effect of Depth and Duration of Cooling on Death or Disability at Age 18 Months Among Neonates With Hypoxic-Ischemic Encephalopathy
- The Frequency and Severity of MRI Abnormalities in Infants with Mild Neonatal Encephalopathy
- MRI as a Biomarker for Mild Neonatal Encephalopathy
- Treating EEG Seizures in Hypoxic Ischemic Encephalopathy: A Randomized Controlled Trial
- Adverse Neurodevelopmental Outcomes after Exposure to Phenobarbital and Levetiracetam for the Treatment of Neonatal Seizures